Precision Biosciences vs Sutro Biopharma
Sutro Biopharma is the larger business, with $102m of revenue in fiscal 2025 against $34.3m for Precision Biosciences (3.0 times as much). Sutro Biopharma grew faster (65.2% against -50.1%). Precision Biosciences kept more of each dollar of sales as profit: a net margin of -133.4% against -186.5%.
| Latest fiscal year | Precision BiosciencesDTIL, 2025 | Sutro BiopharmaSTRO, 2025 |
|---|---|---|
| Revenue | $34.3m | $102m |
| Revenue growth | -50.1% | 65.2% |
| Net income | −$45.7m | −$191m |
| Operating margin | -152.2% | — |
| Net margin | -133.4% | -186.5% |
| Return on equity | -61.5% | — |
| Free cash flow | −$65.9m | −$177m |
| Cash | $111m | $58.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 68 | 137 |
| Market value | $184m | $151m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 6 buys, 11 sales | 0 buys, 0 sales |